HIV mutation literature information.


  Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.
 PMID: 31976534       2020       The Journal of antimicrobial chemotherapy
Abstract: RESULTS: The frequencies of doravirine-associated resistance mutations (total dataset versus NNRTI-failing patients) were: V106A/M, 0.8% versus 2.6%; V108I, 3.3% versus 9.2%; Y188L, 1.2% versus 2.6%; G190S, 0.3% versus 2.1%; F227C/L/V, 0.5% versus 1.8%; M230I/L, 2.8% versus 0%; L234I, 0.1% versus 0.5%; K103N + Y181C, 3.9% versus 3.9%; K103N + P225H, 2.9% versus 4.7%; and K103N + L100I, 1.7% versus 3.9%, with a significantly higher proportion of these mutations in the


  Trend of HIV-1 drug resistance in China: A systematic review and meta-analysis of data accumulated over 17 years (2001-2017).
 PMID: 31922125       2020       EClinicalMedicine
Table: L100I


  Human Immunodeficiency Virus-1 Viral Load Is Elevated in Individuals With Reverse-Transcriptase Mutation M184V/I During Virological Failure of First-Line Antiretroviral Therapy and Is Associated With Compensatory Mutation L74I.
 PMID: 31774913       2020       The Journal of infectious diseases
Result: The following NNRTI mutations were also associated: A98G, L100I, K103R, V108I, Y181C, Y188L, G190A, P225H, L228R, and M230L.


  Virologic suppression in patients with a documented M184V/I mutation based on the number of active agents in the antiretroviral regimen.
 PMID: 33014372       2020       SAGE open medicine
Table: L100I


  Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
 PMID: 32712537       2020       European journal of medicinal chemistry
Abstract: Among all the chiral derivatives, (S)-(-)-12a showed the best potency with the antiviral activities against wild-type (WT) and single mutant strains (L100I, K103 N, Y181C, E138K; especially Y188L), and RT enzyme in the low nanomolar concentration range.


  Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia.
 PMID: 32804970       2020       PloS one
Table: L100I


  Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development.
 PMID: 32925358       2020       Journal of acquired immune deficiency syndromes (1999)
Introduction: Although RT E138K was observed as with the other subtypes, it was followed by RT K101E to yield the unique double substitution RT E138K/K101E instead of E138K/L100I.
Introduction: By contrast, under the same conditions, RT substitutions L100I and K103N were the major substitutions associated with EFV, and E138K and K101P substitutions were the 2 most common resistance pathways in selection studies with RPV.
Introduction: This was followed by the emergence of


  Patterns of acquired HIV-1 drug resistance mutations and predictors of virological failure in Moshi, Northern Tanzania.
 PMID: 32986709       2020       PloS one
Table: L100I


  Two Coselected Distal Mutations in HIV-1 Reverse Transcriptase (RT) Alter Susceptibility to Nonnucleoside RT Inhibitors and Nucleoside Analogs.
 PMID: 30894467       2019       Journal of virology
Introduction: Compound 13 is similar to RPV in terms of its therapeutic index and its antiretroviral efficacy against a panel of HIV-1 mutants containing RT mutations, including L100I, K103N, V106A, E138K, Y181C, Y188L, H221Y, and K103N/Y181C.
Introduction: In those trials, the viruses in participants who failed RPV-containing therapies had the RT mutations L100I, K101E, K103N, V108I, E138K/R, Y1


  Sustained virological response and drug resistance among female sex workers living with HIV on antiretroviral therapy in Kampala, Uganda: a cross-sectional study.
 PMID: 31266818       2019       Sexually transmitted infections
Table: L100I



Browser Board

 Co-occurred Entities




   Filtrator